Company Snapshot

Scribe Therapeutics Inc. investment report

Start with SCTX at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.

Scribe Therapeutics Inc.

NASDAQ:SCTX

Biotechnology

Healthcare
$15.77 -4.80%

-$0.91 today

Market cap
$255.19M
Beta
0.00

Volume 0.27M

Average 0.98M

Intrinsic Value

SCTX Intrinsic Value

Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.

Scribe Therapeutics Inc.

NASDAQ:SCTX

Intrinsic Alpha fair value

Locked

Current Price

$15.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Monitor SCTX

Get notified when the price moves into your range

Use alerts to turn the valuation into an action plan instead of checking the stock manually.

Price alerts

Get notified when SCTX drops below your target

Current price baseline

$15.77

Current price

Current price $15.77

Selected target$12.62

Sign in to activate price alerts.

Price History

How has SCTX traded over time?

Review how the market has priced Scribe Therapeutics Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.

Price history

Dividend-adjusted closing price

Period change

+5.13%

Period high

$37.25

Period low

$15.00

Latest

$15.77

Investment Notes

Capture the investment case

Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.

My notes

Journal entries for SCTX

Sign in to keep notes

Keep your research and decisions in your personal journal.

Sign in / Sign up

Fundamental Analysis

Test company quality against your thesis

Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.

Earnings Quality

Follow revenue through to net income

Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.

SCTX Earnings Waterfall · TTM

NASDAQ:SCTX · Revenue to Net Income

No earnings data available.

Revenue Mix

See which products and regions drive the business

Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.

Revenue by segment

Where SCTX earns its revenue, as reported in company filings

This company does not report revenue segments.

Financial Position

Check what supports the company underneath the income statement

The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.

Balance Sheet

Assets, liabilities & equity

No balance sheet data available.

Cash Generation

Test whether profit turns into cash

Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

No cash flow data available.

Quality Snapshot

Check the numbers that compound value

Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/AN/AN/A
Equity
N/AN/AN/AN/A
Cash
N/AN/AN/AN/A
ROIC
N/AN/AN/AN/A

Analysis

Analysis will appear once enough financial history is available for this company.

Growth Profile

Compare historical growth with forward expectations

Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.

Growth Analysis

Historical CAGR & forward analyst estimates

No growth data available

Management

Judge how Scribe Therapeutics Inc. allocates capital

Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.

Capital Efficiency

Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.

Return Metrics

ROE, ROIC & ROA over time

Management

No return metrics data available.

Dividend Record

A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.

Dividends

Dividend history, growth & yield

Dividends

Yield

—

Annual Div/Share

$0.00

Payout Ratio

—

Frequency

—

Shareholder Yield

—

Next Ex-Date

Not announced

Next Payment

—

Analysis

The current indicated dividend yield is not available.

Owner Returns

Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

No shareholder return data available.

Insider Activity

Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

8

$71.32M

Sells

0

$0.00

Net Transaction Value

+$71.32M

Net buying

Most Active

Aghazadeh Behzad

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 28, 26

Aghazadeh Behzad

Indirect

Buy$144.3K
Jul 27, 26

AH Bio Fund II, L.P.

Indirect

Buy$5M
Jul 27, 26

GORDON CARL L

Indirect

Buy$15M
Jul 27, 26

ORBIMED ADVISORS LLC

Indirect

Buy$15M
Jul 24, 26

Aghazadeh Behzad

Indirect

Buy$1.1M
Jul 24, 26

Aghazadeh Behzad

Indirect

Buy$35M
Jul 23, 26

Lucas Svetlana

Indirect

Buy$45K
Jul 23, 26

Parrot David

Indirect

Buy$20K

Summary

Insiders reported 8 buys worth $71.32M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $71.32M. Aghazadeh Behzad was the most active insider with 3 transactions.

Leadership

Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.

Management

Key executives, compensation & ownership

View management
NameTitleCompensationAgeShares OwnedOwnership %

Benjamin L. Oakes

Co-Founder, President, CEO & ChairmanUSD 574.98K37264.78K1.64%

David L. Parrot

CFO & TreasurerUSD 475.83K57——

Svetlana Lucas

Chief Operating OfficerUSD 466.98K543.00K0.02%

Jennifer A. Doudna

Co-Founder & Scientific Advisor—620<0.01%

David F. Savage

Co-Founder & Scientific Advisor————

Brett T. Staahl

Co-Founder & VP of External Innovation————

George Manning

VP & Controller————

Richard Hector

Head of Intellectual Property————

Sunny Mok

Senior Vice President of Operations————

Chitra Sharma

Senior Vice President of Development————

Stephen V. Thau

Secretary————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 27, 2026.

Alternatives to SCTX

Compare Scribe Therapeutics Inc. with similar companies

A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Analysts

What Wall Street expects from SCTX

Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.

Analyst Targets

See where analysts expect SCTX to trade next

Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for SCTX.

Sign in free

Analyst Ratings

How analysts rate SCTX today

See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for SCTX.

Sign in free

Company Overview

Understand how Scribe Therapeutics Inc. makes money

Ground the financial evidence in the company profile, business description, and key facts.

Key Information

Filings
NameScribe Therapeutics Inc.
TickerSCTX
ExchangeNASDAQ
IPO DateJul 24, 2026
IndustryBiotechnology
SectorHealthcare
Market Cap$255.19M
Shares Out16.18M
LocationAlameda, CA, US

Stock Analysis

Turn the SCTX report into your next decision

Record your conclusion, evidence, and concerns in a structured analysis workspace.

Investment analysis

Turn SCTX research into a decision

Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.

NASDAQ:SCTX
Know the Business
Test the Moat
Management
Intrinsic Value

Sign in on the next page to save a private analysis.

Start analysis

FAQ

Common questions about SCTX

Resolve the remaining questions before moving into the detailed workspaces.

Explore

Continue your research

Open the detailed valuation, financial, health, and management workspaces.